|
|
|
|
|||||
|
|
|
FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be presenting at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:30 p.m. GMT.
A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for at least 30 days following the event.
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
[email protected]
Media
Jenna Urban
CG Life
[email protected]
| 3 hours | |
| Nov-10 | |
| Nov-04 | |
| Nov-03 | |
| Oct-24 | |
| Oct-21 | |
| Oct-02 | |
| Sep-21 | |
| Aug-21 | |
| Aug-07 | |
| Aug-05 | |
| Aug-04 | |
| Jun-23 | |
| May-29 | |
| May-14 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite